

Alain Huriez



Alain Huriez MD, 45, married 4 children, is since mid 2006 Chairman and Chief Executive Officer of TcLand Expression SA. Alain is one the company's co-founders.

From early 2003 to mid 2006 Alain was CEO at Neovacs SA, a company developing therapeutic vaccines that he successfully transformed from an academic structure to an integrated biotechnology company with accelerated drug development programs.

Alain brings an experience of general management and financing in the biotechnology sector, in various executive positions as Associate Partner Biotech at Truffle Capital, a €220m VC fund (2002-2003), Vice-President Quintiles Europe, the world's largest CRO (1999-2002), in charge of the Biotechnology Consulting Group, a separate entity that he founded, specialized in offering strategic counsel to biotechnology listed companies in Europe and the USA. As Vice President of the Biotechnology Consulting Group, Alain set up subsidiaries for TSE/NASDAQ listed biotechnology companies. Alain was also involved with several Bio-Clusters in Europe providing management consulting and guidance to Emerging companies and local incubators.

Alain brings also fifteen years of experience in biotech drug development, from pre-clinical to registration in several positions including European project manager, project director and worldwide program director both in the pharmaceutical industry (GSK) and in the service industry (MDS, Innovex, Quintiles). Alain is M.D., holds a Post Graduate degree in Business Administration (MBA), a Statistics degree from the University of Paris VII, and a Masters of Pharmacoeconomics from the University of Paris I Sorbonne.

Prior to joining the Pharmaceutical Industry, he worked 1 year as head of an emergency room in a large teaching hospital and practised 2 years as General Practitioner.

Alain supports and triggers several biotechnology initiatives in the area of biomarkers and theranostics, is Vice President of LEEM Biotech Committee, expert for Evry's Genopole.